Personalized medicine

August 25, 2023

Amended Trial: Eligibility Expands in the EA8191/INDICATE Trial for Patients with Prostate Cancer

The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence